Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordable for diabetes and obesity management. The company is the first in India to offer this convenient format. This move intensifies competition in the growing Indian drug market. Alkem aims to expand access to quality medicines for better patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZTqrRtK
via IFTTT

Read More

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access for affected nations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZVmTMeO
via IFTTT

Read More

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJinu2r
via IFTTT

Read More

GVK-backed Oval Fertility launched in Hyderabad, eyes share in India's growing IVF market

GVK family-backed Oval Fertility has launched its first premium IVF center in Hyderabad, leveraging advanced embryo monitoring technology. Co-founded by US fertility specialist Dr. Brian Levine and Veena Reddy, the venture aims to redefine fertility care with a blend of science, technology, and personalized patient experience. The clinic, priced at Rs 4.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTjstYo
via IFTTT

Read More

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

Wockhardt’s newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cAJZxhe
via IFTTT

Read More

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S8Y03QR
via IFTTT

Read More

Wockhardt secures US FDA approval for antibiotic Zaynich

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mrkbf30
via IFTTT

Read More